drugset
drugset / Trial / NCT00131989

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00131989 ↗

Phase 1 Completed 48 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of sorafenib in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer

Timeline

Start
2005-06
Primary completion
2007-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule — Oral

Indications

acute basophilic leukemia acute lymphoblastic leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myelomonocytic leukemia M4 acute promyelocytic leukemia adult acute monocytic leukemia erythroleukemia